World Health Organization 1 Pharmacovigilance Dr Shanthi Pal Quality Assurance and Safety of...

1World Health Organization

Pharmacovigilance

Dr Shanthi Pal

Quality Assurance and Safety of Medicines

WHO

2World Health Organization

Objectives

• To discuss the need for pharmacovigilance

• To present WHO’s role in promoting pharmacovigilance

3World Health Organization

Medicine Safety

• To undergo treatment you have to be very healthy, because apart from your sickness you have to stand the medicine.

Molière

4World Health Organization

Pharmacovigilance

What IS this?

5World Health Organization

Vigilance

Vigilare = to watch

alert watchfulness

forbearance of sleep; wakefulness

watchfulness in respect of danger; care; caution; circumspection

the process of paying close and continuous attention

6World Health Organization

Pharmacovigilance

• The science and activities relating to the detection, evaluation, understanding and prevention of adverse drug reactions or any other drug-related problems

7World Health Organization

Pharmacovigilance Major Aims

• early detection of unknown safety problems• detection of increases in frequency• identification of risk factors• quantifying risks• preventing patients from being affected

unnecessarily

Rational and Safe use of Medicines

8World Health Organization

• Pre-marketing safety data

Animal Experiments : Relevant?

Clinical Trials: Complete?

Why Pharmacovigilance?

9World Health Organization

Why Pharmacovigilance?

• Post-marketing Topics Unexpected adverse reactions Interactions Dependence Long-term efficacy, Resistance Risk factors Quality (Counterfeit) Cost assessment

10World Health Organization

Why Pharmacovigilance?

• Adverse Drug Reactions are the 4th to 6th largest cause of mortality in the USA

(Lazarou J. et al., 1998)

11World Health Organization

Why Pharmacovigilance?

The percentage of hospital admissions due to drug related events in some

countries is about or more than 10%.

• UK Study : 10.1 % (Bhalla et al, 2003)

• French study : 10.3 % prevalence of ADRs (Imbs et al, 1999)

12World Health Organization

Why Pharmacovigilance?

Economic impact

Drug related morbidity and mortality expenses exceeded US$ 177.4

billion in the USA in 2000

(Ernst & Grizzle, 2001)

13World Health Organization

WHO Programme for InternationalDrug Monitoring

WHOHQ

WHO CollaboratingCentre, Uppsala

NationalCentres

14World Health Organization

Mary CouperMedical Officer

Lembit RägoCoordinator QSM

Vladimir LepakhinADG/HTP

Caroline Mullen Secretary

Shanthi PalTechnical Officer

Christine EncrenazTechnical OfficerSCRIHS

Safety of Medicines TeamSafety of Medicines TeamSafety of Medicines TeamSafety of Medicines Team

15World Health Organization

WHO Programme for International Drug Monitoring (HQ)

• Policy

• Exchange of Information

• Technical support to countries

• Advisory Committee on Safety of Medicinal Products

16World Health Organization

Exchange of Information

• WHO Pharmaceuticals Newsletter• WHO Drug Alerts• WHO Drug Information• WHO Restricted Pharmaceuticals List• (Vigimed - electronic exchange)• (Uppsala Reports)• (Signal)

17World Health Organization

Technical support to countries

• Technical guidelines on all aspects of pharmacovigilance

(Several publications and documents)• Training courses on

pharmacovigilance

(Regional Training Courses, biennial course by UMC and HQ)

18World Health Organization

19World Health Organization

WHO Collaborating Centre (Uppsala Monitoring Centre)

ADR database• No of reports: more than 3 million• Each year increase ~250,000 / year• Top 5 reporting countries

• USA• United Kingdom• Germany• Australia• Canada

20World Health Organization

WHO Collaborating Centre (Uppsala Monitoring Centre)

ADR Reports• Analysis• Data mining (BCPNN)• Output

– Feedback to National Centres– Signal documents– Ad hoc research results

21World Health Organization

Future challenges

• Raise awareness

• Monitor all medicines

• Integrate work throughout WHO

• Improve training activities

22World Health Organization

In conclusion ….

• The work of WHO in the area of safety monitoring of medicines is necessary if we are to achieve the mission of EDM:

• Medicines should be Available, Affordable, Safe and Properly used.

23World Health Organization

Thank you

‘People who are vigilant do not die; people who are negligent are as if dead’.

- Shakyamuni Buddha